+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years - 99Years
All Genders
ID06736288

Study to Evaluate the Effectiveness and Safety of Buccalin4 Tablets in Preventing Recurrent Lower Respiratory Tract Infections in Adults

Led by Laboratorio Farmaceutico SIT srl · Updated on 2025-12-10

240

Participants Needed

10

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying BUCCALIN4 gastro-resistant tablets to see if they can help prevent recurrent lower respiratory tract infections RLRTIs and to evaluate the safety of this treatment. The main goal is to reduce the number of infection episodes during a 12-month treatment period compared to a placebo group. This phase 4 clinical trial includes adults aged 18 to 99 years who have experienced repeated respiratory infections and meet specific criteria for participation. The study has three phases over a total of 36 months. It starts with a 12-month run-in phase where patients receive no treatment to monitor infection episodes and improve adherence. Patients experiencing at least two infection episodes during this time may enter the 12-month treatment phase, where they receive either BUCCALIN4 tablets or placebo tablets. The medication is taken for 3 days each month in a specific dosage schedule. After treatment, there is a 12-month follow-up phase with no treatment to observe ongoing effects. Throughout the study, participants will attend several visits for assessment. Researchers will monitor infection episodes and safety outcomes from enrollment through the end of the treatment phase. The primary measurement is the number of infection episodes during the 12-month treatment. The study also tracks adherence and collects clinical data during the run-in, treatment, and follow-up phases to evaluate the overall impact of BUCCALIN4 compared to placebo.

CONDITIONS

Brief Title

Post Authorization Efficacy and Safety Study (PAES) to Confirm and Collect More Clinical Data of Buccalin® Tablets In the Prophylaxis of Recurrent Lower Respiratory Tract Infections (RLRTIs).

Research Team

S

Silvana Lonetti

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here